A new CRISPR startup — backed by some big names in venture capital — is planning to develop gene-editing treatments that can insert a genetic sequence of any length, at any location in the DNA strand, according to industry insiders and documents.
The biotech is called Tome Biosciences, and it hopes to write the next chapter in genomic medicines. It’s backed by Arch Venture Partners, Andreessen Horowitz, and the Longwood Fund, which have closed a Series A round of financing.
“I’ve been working in gene therapy for 23 years now, and this is the tool I’ve been waiting for that entire time,” Chief Scientific Officer Jonathan Finn said in April during a public meeting in Watertown, Mass., where the company is headquartered.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect